Herpes Virus (Vzv, Hsv1, Hsv2), Dna Detection Assay For Cutaneous And Mucocutaneous Lesion Samples
PGI is the FDA product code for Herpes Virus (Vzv, Hsv1, Hsv2), Dna Detection Assay For Cutaneous And Mucocutaneous Lesion Samples, a class II device type, regulated under 21 CFR 866.3309. FDA's definition for this code reads: "For the qualitative detection and differentiation of VZV, HSV1, HSV2- DNA in cutaneous and mucocutaneous lesion samples from symptomatic patients. The assay is not intended for use with cerebral spinal fluid". As of , FDA records hold 9 510(k) clearances under this code, the most recent dated , and 2 recalls.
Classification record
- Product code
- PGI
- Device name
- Herpes Virus (Vzv, Hsv1, Hsv2), Dna Detection Assay For Cutaneous And Mucocutaneous Lesion Samples
- FDA definition
- For the qualitative detection and differentiation of VZV, HSV1, HSV2- DNA in cutaneous and mucocutaneous lesion samples from symptomatic patients. The assay is not intended for use with cerebral spinal fluid.
- Regulation
- 21 CFR 866.3309
- Device class
- Class II
- Review panel
- Microbiology
- Submission type
- 510(k)
- Implant
- No
- Life sustaining or supporting
- No
- GMP exempt
- No
- Third party review eligible
- No
- Ingested clearances
- 9
- Ingested recalls
- 2
Clearances, product code PGI
By decision yearShow the numbers
| Year | Clearances |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2023 | 1 |
| 2024 | 1 |
Applicants with the most clearances
Product code PGI| Applicant | Clearances |
|---|---|
| Ortho-Clinical Diagnostics, Inc. | 3 |
| DiaSorin Molecular LLC | 2 |
| Abbott Molecular, Inc. | 1 |
| ELITechGroup Inc | 1 |
| Luminex Corporation | 1 |
| Meridian Bioscience Inc | 1 |
Companies listing this code with FDA
Companies whose registered establishments list this codeFIRST ARTICLE / WEEKLY
What cleared, what was recalled, and what changed in the standards. One edition a week for the people who make medical devices.
